pGMEH-P38-che-ssrAec3 Citations (3)

Originally described in: Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase.
Kim JH, Wei JR, Wallach JB, Robbins RS, Rubin EJ, Schnappinger D Nucleic Acids Res. 2011 Mar;39(6):2210-20. doi: 10.1093/nar/gkq1149 PubMed Journal

---

Articles Citing pGMEH-P38-che-ssrAec3

Articles
Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ, Yap A, Fulwood J, Lakshmanan U, Lim J, Khoo AY, Flotow H, Hill J, Raju RM, Rubin EJ, Dick T. MBio. 2015 May 5;6(3):e00253-15. doi: 10.1128/mBio.00253-15. PubMed
Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome. Moreira W, Santhanakrishnan S, Ngan GJY, Low CB, Sangthongpitag K, Poulsen A, Dymock BW, Dick T. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02307-16. doi: 10.1128/AAC.02307-16. Print 2017 May. PubMed
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome. Moreira W, Santhanakrishnan S, Dymock BW, Dick T. Front Microbiol. 2017 Apr 27;8:746. doi: 10.3389/fmicb.2017.00746. eCollection 2017. PubMed

If you have published an article using this material, please email us at to have your article added to this page.